Evidence map›Paper›PMID 28743298›Full record

ArticleJournal of ovarian research2017

R-spondin2, a novel target of NOBOX: identification of variants in a cohort of women with primary ovarian insufficiency.

Justine Bouilly, Isabelle Beau, Sara Barraud, Valérie Bernard, Brigitte Delemer, Jacques Young, Nadine Binart

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Justine BouillyInserm U1185, Faculté de Médecine Paris Sud 63, Univ Paris Sud, Université Paris-Saclay, rue Gabriel Péri, 94276, Le Kremlin-Bicêtre Cedex, France. justine.bouilly@gmail.com.
Isabelle BeauInserm U1185, Faculté de Médecine Paris Sud 63, Univ Paris Sud, Université Paris-Saclay, rue Gabriel Péri, 94276, Le Kremlin-Bicêtre Cedex, France.
Sara BarraudInserm U1185, Faculté de Médecine Paris Sud 63, Univ Paris Sud, Université Paris-Saclay, rue Gabriel Péri, 94276, Le Kremlin-Bicêtre Cedex, France.
Valérie BernardInserm U1185, Faculté de Médecine Paris Sud 63, Univ Paris Sud, Université Paris-Saclay, rue Gabriel Péri, 94276, Le Kremlin-Bicêtre Cedex, France.
Brigitte DelemerService d'Endocrinologie-Diabète-Nutrition, CHU de Reims-Hôpital Robert-Debré, 51092, Reims, France.
Jacques YoungInserm U1185, Faculté de Médecine Paris Sud 63, Univ Paris Sud, Université Paris-Saclay, rue Gabriel Péri, 94276, Le Kremlin-Bicêtre Cedex, France.
Nadine BinartInserm U1185, Faculté de Médecine Paris Sud 63, Univ Paris Sud, Université Paris-Saclay, rue Gabriel Péri, 94276, Le Kremlin-Bicêtre Cedex, France.
Université Paris-Saclay · FRCentre Hospitalier Universitaire de Reims · FRInserm · FRUniversité de Reims Champagne-Ardenne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundR-spondin2 (Rspo2) is a secreted agonist of the canonical Wnt/β-catenin signaling pathway. Rspo2 plays a key role in development of limbs, lungs and hair follicles, and more recently during ovarian follicle development. Rspo2 heterozygous deficient female mice become infertile around 4 months of age mimicking primary ovarian insufficiency (POI). The study aimed to investigate the regulation of RSPO2 and its potential involvement in pathophysiology of POI.

methodsWe cloned the RSPO2 promoter and performed transcriptional assays to determine if RSPO2 can be regulated by NOBOX, an ovarian transcription factor. Then, we evaluated 100 infertile women after obtaining a detailed history of the disease and follicle-stimulating hormone measurements, besides karyotype determination and fragile-X premutation syndrome investigation. All exons, intron-exon boundaries and untranslated regions of the RSPO2 gene were identified by sequencing, and the results were statistically analyzed.

resultsWe found that RSPO2 can be regulated by NOBOX via the presence of NOBOX Binding Element in its promoter. Among 9 identified variants in POI women, 4 of them were equally homozygous, 4 have never been described (c.-359C > G, c.-190G > A, c.-170 + 13C > T and c.-169-8 T > A), only one c.557 T > C was predicted to alter a single amino acid in the RSPO2 protein (p.Leu186Pro).

conclusionsRSPO2 is a novel target gene of the NOBOX key transcription factor, confirming its important role during the follicular growth in ovary. However, RSPO2 mutations are rare or uncommon in women with POI.

Indexed as

AdolescentAdultAnimalsChlorocebus aethiopsCOS CellsFemaleHomeodomain ProteinsHumansInfertility, FemaleIntercellular Signaling Peptides and ProteinsPolymorphism, Single NucleotidePrimary Ovarian InsufficiencyR-SpondinsTranscription FactorsYoung AdultHomeodomain ProteinsIntercellular Signaling Peptides and ProteinsNOBOX protein, humanRspo2 protein, humanR-SpondinsTranscription FactorsFolliculogenesisGenetic variantsPrimary ovarian insufficiency (POI)RSPO2

Identifiers

PMID28743298
PMCPMC5526297
OpenAlexW2736936137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.